AMRI's revenues soar 45% as refocus on contract manufacturing pays off

AMRI ($AMRI), having refocused on its contract manufacturing operations, saw the changes pay off last year, according to its recently released earnings. The Albany, NY-based CDMO reported that revenue grew 45% in 2015, to $402.3 million, up from $276.6 million from the previous year. The contractor has moved from its heavy reliance on drug discovery to more emphasis on production, adding plants and capabilities through a series of deals in the last two years. More from FierceCRO